Cargando…

Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors

Tisotumab vedotin is an investigational antibody–drug conjugate (ADC) for treatment of solid tumors expressing tissue factor with accelerated approval from the US Food and Drug Administration for treatment of recurrent or metastatic cervical cancer with disease progression during or after chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gibiansky, Leonid, Passey, Chaitali, Voellinger, Jenna, Gunawan, Rudy, Hanley, William D., Gupta, Manish, Winter, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574719/ https://www.ncbi.nlm.nih.gov/pubmed/35932175 http://dx.doi.org/10.1002/psp4.12850

Ejemplares similares

Exposure‐safety and exposure‐efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors
por: Passey, Chaitali, et al.
Publicado: (2023)

Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study
por: Yonemori, Kan, et al.
Publicado: (2022)

Tisotumab Vedotin Safety and Tolerability in Clinical Practice: Managing Adverse Events
por: Arn, Courtney R., et al.
Publicado: (2023)

Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data
por: Agostinelli, Veronica, et al.
Publicado: (2023)

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma
por: Lu, Dan, et al.
Publicado: (2019)

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma
por: Lu, Dan, et al.
Publicado: (2020)

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
por: Shi, Rong, et al.
Publicado: (2020)

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
por: Gibiansky, Ekaterina, et al.
Publicado: (2021)

Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context
por: Hoffman-Censits, Jean, et al.
Publicado: (2022)

Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review
por: Bantounou, Maria A., et al.
Publicado: (2023)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study
por: Gibiansky, Ekaterina, et al.
Publicado: (2019)

A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
por: Takahashi, Shunji, et al.
Publicado: (2019)

Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
por: Fahey, Catherine C., et al.
Publicado: (2023)

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30‐Expressing Hematologic Malignancies
por: Li, Hong, et al.
Publicado: (2017)

Brentuximab Vedotin
Publicado: (2012)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
por: Kawahara, Takashi, et al.
Publicado: (2023)

A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma
por: Hasanov, Merve, et al.
Publicado: (2020)

Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors
por: Fujiwara, Yutaka, et al.
Publicado: (2021)

Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT
por: Giza, Agnieszka, et al.
Publicado: (2023)

Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
por: Wang, Xiaofeng, et al.
Publicado: (2020)

Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin
por: Jain, Rohit K, et al.
Publicado: (2020)

Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma
por: Enescu, Christina D., et al.
Publicado: (2022)

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma
por: Adib, Elio, et al.
Publicado: (2021)

Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure–Response in CLL
por: Gibiansky, E, et al.
Publicado: (2014)

Enfortumab Vedotin in urothelial cancer
por: Alt, Marie, et al.
Publicado: (2020)

Brentuximab vedotin induced uveitis
por: Therssen, Stijn, et al.
Publicado: (2022)

Drug extravasation with Enfortumab vedotin
por: Grant, Christopher Ryan, et al.
Publicado: (2023)

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
por: Shemesh, Colby S., et al.
Publicado: (2020)

Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate
por: Pouzin, Clemence, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis
por: Wei, Xiaohui, et al.
Publicado: (2017)

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
por: Rosenberg, Jonathan, et al.
Publicado: (2020)

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

Brentuximab vedotin: axonal microtubule's Apollyon
por: Mariotto, S, et al.
Publicado: (2015)

Flexural Exanthema From Enfortumab Vedotin
por: Keerty, Dinesh, et al.
Publicado: (2020)

Polatuzumab Vedotin: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)

Polatuzumab vedotin for B-cell lymphoma
Publicado: (2020)

Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors
por: He, Jimmy, et al.
Publicado: (2022)

Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants
por: Gibiansky, Leonid, et al.
Publicado: (2020)

Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
por: Isoda, Bunpei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o6apd9o1mq19dv3bp5mvjp8tul